Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

Search results for: heart disease

Transbronchial Lung Cryobiopsy a Valid Diagnostic Option in Interstitial Lung Disease

Reuters Staff  |  

NEW YORK (Reuters Health)—Transbronchial lung cryobiopsy (TBLC) and surgical lung biopsy (SLB) had a high level of agreement for diagnosing interstitial lung disease in the first comparative study. “These data suggest that TBLC, when done by an experienced proceduralist, is a valid first-line minimally invasive diagnostic tool for patients with interstitial lung disease deemed to…

Myocardial Inflammation Associated with RA Disease Activity

  |  

Introduction: Heart failure, a key contributor to cardiovascular disease (CVD) morbidity and mortality, is associated with fewer symptoms and higher (preserved) ejection fraction, but higher mortality rates, in rheumatoid arthritis (RA) patients than among those in the general population. In the general population, higher levels of circulating proinflammatory cytokines, such as tumor necrosis factor (TNF)…

Women Diagnosed Years Later than Men for Same Diseases

Tamara Mathias  |  

(Reuters Health)—For a wide range of diseases, diagnosis comes later in life for women than for men, according to a large Danish study. Researchers don’t know whether the later diagnoses are due to genetics, the environment, possible biases in the healthcare system—or some combination of reasons. The study of health data from 6.9 million Danish…

Lightspring / shutterstock.com

Recent Research Probes Smoking & the Risk for Autoimmune Disease

  |  

It’s no secret to any health professional, including rheumatologists, that smoking cigarettes or using other tobacco-based products is unhealthy. Yet how does smoking specifically affect rheumatic diseases, and what are some of the newest findings in this area? What role do e-cigarettes have in the smoking risk landscape? Those are the sorts of questions asked…

FDA Rejects Novartis Bid to Repurpose Inflammation Drug for Heart Attacks

John Miller  |  

ZURICH (Reuters)—The U.S. Food and Drug Administration (FDA) has rejected Novartis’s bid to repurpose a drug now approved for rare inflammatory diseases to be used in a group of heart attack survivors, according to the Swiss drugmaker. The company received an FDA letter turning down its bid to make canakinumab a targeted therapy for those…

A Historical Look at the Characterization of Lupus as a Systemic Disease

  |  

The disease called systemic lupus erythematosus (SLE) went through many different stages of classification before reaching the modern criteria reflecting our current understanding of its pathogenesis. In 1872, the Viennese dermatologist Moriz Kaposi, MD, published a paper, “New Contributions to Knowledge of Lupus Erythematosus,” which provided a significant leap forward in the characterization of this…

Help Your Patients Live Well with Rheumatic Disease

David Daikh, MD, PhD  |  

As rheumatology professionals, we focus on how to achieve better outcomes for our patients: lower disease activity, remission, milder symptoms and prevention of joint damage or serious complications, such as heart disease. Another outcome is just as important: good quality of life. What can we do to engage our current patients and those at risk…

Study Finds Newer Gout Drug Poses Risk to Heart Patients

Gene Emery  |  

(Reuters Health)—Gout sufferers with major pre-existing heart disease face a higher risk of death if they are treated with the drug febuxostat, a large long-term study has concluded. The risk of death from cardiovascular disease was 34% higher with febuxostat than with allopurinol. When researchers considered deaths from any cause, the risk was 22% higher…